Check out today’s @NEJM publication on Acquired Resistance to KRASG12C Inhibition in Cancer showing oncogene amplification as a resistance mechanism. Our CTO, Jason Christiansen, is a co-author. #ecDNA https://t.co/L5veLY6OX0
Congratulations to our Venture Advisor @gsg907 and @Obsidian_Tx 's founder @michael_gilman for being recognized for your legacy! We are privileged to work with you and many others on this great list.
Big team effort here, and a lot of fun:
Legacies: 60 biopharma pioneers over 60 who helped birth a tech revolution in the making
https://t.co/iVb1e3kWsR
We are excited for @BoundlessBio's successful Series B fundraise! Looking forward to continue working with the fantastic team and syndicate to develop therapeutics targeting #ecDNA for #oncology. Congratulations, the @BoundlessBio team!
Congrats to the @BoundlessBio team and welcome @NextechInvest and RA Capital, as well as the other new investors. Thanks for your support as the team continues to push the frontier targeting #ecDNA in #oncology. Well done, @ZacharyHornby and team!
$VRTX is one of the most interesting R&D partners now in play...
Vertex adds a new gene editing partner, paying Obsidian $75M for controllable CRISPR system
https://t.co/51cJuQkkq7
Check out The Scientist’s feature article on #ecDNA, written by our scientific founder, @mischellab. Paul discusses the foundational research on resistance to targeted therapies in gene amplified cancers that led to the formation of Boundless Bio. https://t.co/tCLSiZSt9Z
Later today Palleon co-founder @CarolynBertozzi will be among the biotech founders speaking at the “Women Who Lead in Life Sciences” event by @SFBusinessTimes. Learn more: https://t.co/F2oY2e6Fv0 #SFBTwomenwholead
Congrats to @elevatebio for its Series C! Particularly proud of how the team's executing on what we consider to be a very innovative and pragmatic business model for #cellandgenetherapy.
Tomorrow, Bicycle’s CEO Kevin Lee and @Roche’s head of pharma partnering James Sabry will discuss early-stage collaborations between biotechs and big pharma. To join the conversation, register here: https://t.co/0F09o227jf
#Partnerships#StrongerTogether
You know these guys? You should --
George Golumbeski and Faheem Hasnain team up with Vertex Ventures HC in managing $320M of biotech cash
By @MaxGelman
https://t.co/NNQtbEW05i
Huge welcome to Faheem Hasnain and George Golumbeski to the Vertex Ventures HC Fund. We are excited to work with you to make an impact in healthcare innvoation. https://t.co/Bv9459VOpS
My first pre-recorded Zoom panel: deco not used to seeing and hearing myself on video afterwards. Fun panel tho with Thomas Hudson @abbvie, Ferran Prat @MDAndersonNews Ann Marie @OncoSynergy and @Asthika kicking ass as a fab moderator. #BIFdigital#BIODigital
Joining the virtual @alliancerm Cell & Gene Meeting on the Mesa? Hear from our CSO and President of BaseCamp, Dr. Mitch Finer, about how we’re re-envisioning the way cell and gene therapies are developed and manufactured #Mesa20#cellandgenetherapy https://t.co/ALc37DHvN6
Dr. Landon Edgar will be presenting his work on invigorating T cells through carbohydrate editing from Professor James C. Paulson’s lab, one of our SAB members, at the GlycoNet/ACS Carb Div. Webinar today: https://t.co/BVJ2Dlc7Yz Watch the video later: https://t.co/QGUqJLfwMq